Four anti-tau monoclonal antibody therapies, gosuranemab, tilavonemab, semorinemab, and zagotenemab, target epitopes N-terminal to the RD and have all failed in phase II clinical trials for either AD or PSP (32, 33, 34, 35, 36, 37, 38). Here, MAPT is linked to Alzheimer disease.